Single-Domain Antibodies for Diagnostics and Therapeutic applications

NanoTag´s own programs have resulted in the development and characterization of several single-domain antibodies specific to targets with therapeutic and diagnostic potential.

NanoTag is looking for B2B opportunities to bring these or new single-domain antibodies to the next level. Please contact us if you have interest in partnering with us.

Contact
Target CD19
Partnership Own program; Project open for collaboration
Immunizations
Discovery
Pre-clinical
Clinical
Description
Target CD45
Partnership Own program; Project open for collaboration
Immunizations
Discovery
Pre-clinical
Clinical
Description
Target CD56 (Neural Cell Adhesion Molecule, NCAM)
Partnership Own program; Project open for collaboration
Immunizations
Discovery
Pre-clinical
Clinical
Description
Target CD127 (Interleukin-7 Receptor subunit alpha, IL-7Rα)
Partnership Own program; Project open for collaboration
Immunizations
Discovery
Pre-clinical
Clinical
Description
Target TNFa
Partnership Own program; Project open for collaboration
Immunizations
Discovery
Pre-clinical
Clinical
Description
Target IgM
Partnership Own program; Project open for collaboration
Immunizations
Discovery
Pre-clinical
Clinical
Description
Target CD62L (L-Selectin)
Partnership Own program; Project open for collaboration
Immunizations
Discovery
Pre-clinical
Clinical
Description
Target Human Serum Albumin (HSA)
Partnership Own program; Project open for collaboration
Immunizations
Discovery
Pre-clinical
Clinical
Description

Superior affinity reagents for R&D and Therapy

Our goal is to provide high-quality recombinant affinity molecules supporting therapeutic and diagnostic industries and to create superior, sustainable, and more reproducible reagents for biomedical research.
Learn more